{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-073897","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.997462+00:00","generated_at":"2026-06-04T10:55:24.755936+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Heron Therapeutics designates Ira Duarte as principal accounting officer, replacing Lisa Peraza","bullets":["Ira Duarte appointed principal accounting officer effective March 29, 2024, succeeding Lisa Peraza.","Lisa Peraza will remain as chief accounting officer until her employment ends on the effective date.","No additional compensation or adjustments for Duarte in connection with the new role.","Duarte already serves as EVP and CFO; no family relationships or related party transactions with the company."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-073897","json":"https://secwatch.observer/filing/0001193125-24-073897.json","markdown":"https://secwatch.observer/filing/0001193125-24-073897.md","text":"https://secwatch.observer/filing/0001193125-24-073897.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000119312524073897/0001193125-24-073897-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000119312524073897/d801406d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T10:55:24.755936+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2348d3d264","claim":"Ira Duarte changed role as principal accounting officer at HERON THERAPEUTICS, INC. /DE/.","evidence_excerpt":"On March 18, 2024, Ira Duarte was designated as Heron Therapeutics, Inc.’s principal accounting officer, replacing Lisa Peraza, the Company’s current Chief Accounting Officer and principal accounting officer, effective March 29, 2024 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818033/000119312524073897/0001193125-24-073897-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"designated"},{"label":"Role","value":"principal accounting officer"}],"fact_type":"executive_change"},{"claim_id":"e272cd3a75","claim":"Lisa Peraza departed as Chief Accounting Officer at HERON THERAPEUTICS, INC. /DE/.","evidence_excerpt":"Ms. Peraza will continue to serve in her current position until her employment with the Company ends on the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818033/000119312524073897/0001193125-24-073897-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ends"},{"label":"Role","value":"Chief Accounting Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}